Trevogrumab

Buy Trevogrumab Online

Trevogrumab is a monoclonal antibody designed to inhibit myostatin (GDF-8). It has been investigated as a strategy for preserving skeletal muscle during weight loss and for modifying muscle-related outcomes.

Product Information

Trevogrumab is an investigational anti-myostatin antibody developed by Regeneron. By binding myostatin, it is intended to reduce signaling that normally restrains skeletal muscle growth. Clinical development has increasingly examined its use alongside obesity therapies.

How It Works

Trevogrumab binds myostatin and prevents it from activating its normal signaling pathway. Because myostatin acts as a negative regulator of skeletal muscle growth, blocking the pathway can alter muscle mass and composition.

POTENTIAL BENEFITS

1. Myostatin Research

Trevogrumab provides a targeted way to investigate the biological role of myostatin in humans. Blocking GDF-8 signaling allows researchers to study how this pathway influences muscle maintenance.

2. Muscle-Preservation Research

Recent clinical development has focused on whether myostatin inhibition can preserve lean mass during substantial weight loss. A 2026 clinical report evaluated trevogrumab alongside semaglutide in adults with obesity.

3. Body-Composition Research

The compound is relevant to research distinguishing total weight reduction from changes in lean and fat mass. This is particularly important in metabolic research where body composition is an important endpoint.

4. Muscle-Regeneration Research

Myostatin signaling is closely involved in skeletal-muscle growth and remodeling. Trevogrumab therefore provides a research tool for examining whether targeted inhibition can modify muscle physiology.

Dosage

Trevogrumab remains investigational, so there is no established clinical dosage for general use. Recent clinical research has evaluated doses including 75 mg, while other trial programs have investigated different dose levels and schedules. These remain study-specific exposures rather than an established treatment regimen.

Side Effects

The safety profile remains under clinical investigation. As an antibody targeting a major muscle-growth pathway, potential effects must be evaluated through controlled trials rather than inferred solely from preclinical myostatin research.

References

1. Recent trevogrumab/semaglutide clinical-trial report
2. Trevogrumab and myostatin inhibition — PubMed
3. Myostatin inhibition and skeletal-muscle biology — PubMed

Note: BehemothLabz does not sell this product. Purchase links on this page may direct you to third-party suppliers through affiliate links.

Please click here to see how purchases actually work on this site.